Alirocumab and cardiovascular outcomes according to sex and lipoprotein(a) after acute coronary syndrome: a report from the ODYSSEY OUTCOMES study.

Vera A BittnerGregory G SchwartzDeepak L BhattTerrance ChuaH Asita De SilvaRafael DiazShaun G GoodmanRobert A HarringtonJ Wouter JukemaJennifer McGinnissRobert PordyGenevieve GaronMichel ScemamaHarvey D WhitePh Gabriel StegMichael Szareknull null

Published in: Journal of clinical lipidology (2024)

Alirocumab improves cardiovascular outcomes after ACS irrespective of sex. Reduction of total cardiovascular events was greater at higher baseline lipoprotein(a).

Keyphrases

cardiovascular events
acute coronary syndrome
low density lipoprotein
coronary artery disease
percutaneous coronary intervention
cardiovascular disease
antiplatelet therapy
type diabetes
atrial fibrillation
glycemic control